Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106945 · ClinicalTrials.gov registry record · Phase 1
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 226
- Enrollment target
- 20
- Study locations
NCT06106945: Recruiting Phase 1 study of Multiple Myeloma, sponsored by AstraZeneca.
NCT06106945 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 226 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06106945, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 226 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.
Primary Outcome
A DLT is any toxicity occuring from the first dose of AZD0305 up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation and which includes, any death not clearly due to the underlying disease or extraneous causes, pre-defined haematological and non-haematological toxicities
Conditions Studied
Interventions
- DRUG AZD0305
Study Locations (20)
Other
- Research Site - Melbourne
- Research Site - Nedlands
- Research Site - Nova Scotia
- Research Site - Beijing
- Research Site - Changsha
- Research Site - Guangzhou
- Research Site - Shenyang
- Research Site - Lille
California
- Research Site - Duarte
- Research Site - Irvine
Ontario
- Research Site - Hamilton
- Research Site - Ottawa
Georgia
- Research Site - Atlanta
Massachusetts
- Research Site - Boston
Michigan
- Research Site - Ann Arbor
Missouri
- Research Site - St Louis
New York
- Research Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2027-08-16 |
| Phase | Phase 1 |
What NCT06106945 shows while recruiting
NCT06106945 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which AZD0305 is the first listed.
NCT06106945 names 20 study sites across 11 states, led by Other, California, Ontario.
Frequently Asked Questions
What is clinical trial NCT06106945 about?
NCT06106945 is a clinical study titled "AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma". This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.
What is the current status of trial NCT06106945?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 226 participants. The study started on 2023-12-05. Estimated completion is 2027-08-16.
What conditions does trial NCT06106945 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06106945?
The interventions under investigation include: AZD0305 (DRUG).
Who is sponsoring clinical trial NCT06106945?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06106945 being conducted?
This trial has 20 study locations across California, Georgia, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06106945's enrollment target sits among peer trials
226 98th of 438 higher than 340 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI